You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Managing Treatment-Naive Chronic Lymphocytic Leukemia With BTK Inhibitors: Test Your Skills

  • Authors: Matthew S. Davids, MD, MMSc
  • CME / ABIM MOC / CE Released: 2/24/2023
  • Valid for credit through: 2/24/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.0 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, pharmacists, nurse practitioners, nurses, and other clinicians who treat patients with CLL.

The goal of this activity is for learners to be better able to understand the safety and efficacy data on available Bruton tyrosine kinase (BTK) inhibitors in CLL and improve their skills in managing treatment-related adverse events.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Data informing the selection of BTK inhibitors for patients with CLL
    • Patient- and disease-specific considerations in the selection of BTK inhibitors for the treatment of CLL
  • Have greater competence related to
    • Managing treatment-related adverse events in patients receiving BTK inhibitors for the treatment of CLL
    • Selecting BTK inhibitors in the management of patients with previously untreated CLL
  • Demonstrate greater confidence in their ability to
    • Work as a part of an interprofessional care team to manage patients with BTK inhibitor therapies in the treatment of CLL


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Matthew S. Davids, MD, MMSc

    Associate Professor of Medicine
    Harvard Medical School
    Director of Clinical Research
    Division of Lymphoma
    Dana-Farber Cancer Institute
    Boston, Massachusetts


    Matthew S. Davids, MD, MMSc, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc; Adaptive Biotechnologies; Aptitude Health; Ascentage Pharma; AstraZeneca; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals; Lilly; MEI Pharma, Inc.; Merck & Co., Inc.; Ono Pharmaceuticals Co., Ltd.; Pharmacyclics, Inc.; Takeda; TG Therapeutics, Inc.; Verastem, Inc.
    Research funding from: Ascentage Pharma; AstraZeneca; Genentech, Inc.; MEI Pharma; Novartis Pharmaceuticals; Pharmacyclics, Inc.; Surface Oncology; TG Therapeutics, Inc.; Verastem, Inc.


  • Charlotte Warren

    Senior Director, Content Development, Medscape, LLC


    Charlotte Warren has no relevant financial relationships.

  • Lisa Cockrell, PhD

    Medical Writer, Medscape, LLC


    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-057-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Managing Treatment-Naive Chronic Lymphocytic Leukemia With BTK Inhibitors: Test Your Skills

Authors: Matthew S. Davids, MD, MMScFaculty and Disclosures

CME / ABIM MOC / CE Released: 2/24/2023

Valid for credit through: 2/24/2024, 11:59 PM EST


The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.


A 58-year-old man presents for a routine workup prior to elective knee surgery. He is a prior smoker and maintains an active lifestyle. While reviewing his laboratory results, his clinician notes that he has a high white blood cell (WBC) count (55 x 109/L). When the clinician asks, the patient reports no symptoms, and he states that he is "as active as ever". A follow-up blood draw 2 months later shows a similar result, and the patient is referred to a hematologist. The hematologist begins a full workup, including ultimately flow cytometry that leads to a diagnosis of chronic lymphocytic leukemia (CLL) with a CD5/CD23-positive monoclonal B-cell population in the peripheral blood. Testing also determines that the patient has high-risk CLL, with del(17p), using fluorescence in situ hybridization (FISH), and a TP53 mutation. In addition, sequencing reveals that he has IGHV unmutated disease. The patient is asymptomatic at this time.


  • Print